ArticleScientific reports2016
A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses.NPJ vaccines · 2025Article
- Sterile protection againstLife science alliance · 2024Article
- Construction, Expression, and Evaluation of the Naturally Acquired Humoral Immune Response againstInternational journal of molecular sciences · 2023Article
- A multivalentBioengineering & translational medicine · 2023Article
- A reverse vaccinology approach on transmembrane carbonic anhydrases from Plasmodium species as vaccine candidates for malaria prevention.Malaria journal · 2022Article
- Review
- Review
- Article
- Natural infections with different Plasmodium species induce antibodies reactive to a chimeric Plasmodium vivax recombinant protein.Malaria journal · 2021Article
- Review
- Progress towards the development of aExpert review of vaccines · 2021Review
- Protective Immunity in Mice Immunized WithFrontiers in immunology · 2020Article
- Antibody responses within two leading Plasmodium vivax vaccine candidate antigens in three geographically diverse malaria-endemic regions of India.Malaria journal · 2019Article
- A Multi-StageFrontiers in cellular and infection microbiology · 2019Article
- Article
- A Large Size Chimeric Highly Immunogenic Peptide Presents Multistage Plasmodium Antigens as a Vaccine Candidate System against Malaria.Molecules (Basel, Switzerland) · 2017Article
- Evaluation of a Major Surface Antigen ofFrontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
The most widespread Plasmodium species, Plasmodium vivax, poses a significant public health threat. An effective vaccine is needed to reduce global malaria burden. Of the erythrocytic stage vaccine candidates, the 19 kDa fragment of the P. vivax Merozoite Surface Protein 1 (PvMSP1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.